Publication
Loureirin A, derived from Dragon's blood, promoted drug delivery and efficacy in pancreatic cancer via vascular promotion.
Jing Wang, Xinchen Liu, Xiusong Tang, Songyan Gao, Shudong Zhang, Yan Wei, Hongbo Li
Biochemical and biophysical research communicationsOct 8, 2026PMID 42659860doi:10.1016/j.bbrc.2026.154461 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260918-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Chemotherapy is a mainstream treatment for pancreatic cancer. Unfortunately, it exhibits a marginal efficacy, partly because the sparse and dysfunctional vasculature in pancreatic cancer has substantially prevented the delivery of chemotherapeutic agents to tumor cells. Vascular promotion, which…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.